查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088825

寡核苷酸合成市場：依產品類型、合成規模、交付方式、應用和最終用戶分類－2026-2032年全球市場預測

Oligonucleotide Synthesis Market by Product Type, Synthesis Scale, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，寡核苷酸合成市場將成長至 316.9 億美元，複合年成長率為 17.43%。

主要市場統計數據
基準年 2025 102.8億美元
預計年份：2026年 120.2億美元
預測年份：2032年 316.9億美元
複合年成長率 (%) 17.43%

寡核苷酸合成是精準醫療、分子診斷、合成生物學和基因組研究的核心基礎技術。此領域包括客製化DNA和RNA寡核苷酸、反義寡核苷酸、siRNA、適配體、CRISPR引導的RNA、引子、探針和修飾核酸，主要透過固相亞磷醯胺化學法生產。

需求主要受FDA已通過核准的分子檢測、不斷擴展的基因組測序工作流程以及已通過核准的RNA標靶治療（如nusinersen、patisirane、gibosilane、inclisilane和tofersen）的推動。隨著治療產品線的日益成熟，買家對寡核苷酸合成供應商的評估也越來越嚴格，評估指標包括GMP合規能力、分析品質、修飾範圍、交貨經驗、監管文件以及供應鏈可靠性。

寡核苷酸產業的變革性變化

寡核苷酸合成領域正從研究規模的訂單生產轉向臨床和商業化生產。治療性寡核苷酸需要嚴格控制序列準確性、雜質譜、內毒素和殘留溶劑，並需要使用液相層析質譜儀（LC-MS）、高效能液相層析（HPLC）、毛細管電泳和核磁共振（NMR）等方法進行鑑定。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過加速序列選擇、脫靶篩檢、二級結構預測、免疫抗原性評估和可生產性評估，正在改善寡核苷酸藥物的發現和生產。人工智慧模型擴大與公共基因組資料庫、RNA 表達資料集和高性能篩檢結果相結合，以便在進行昂貴的實驗室檢驗之前優先篩選候選物質。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

隨著中國、印度、日本、韓國和澳洲不斷擴大基因組學、疫苗和生物製藥的生產能力，亞太地區的重要性日益凸顯。中國憑藉其規模優勢、國內生物技術需求以及活躍的核酸研究，在相關領域佔據領先地位。印度則提供具有成本競爭力的生產製造、臨床研究服務以及不斷改進的診斷基礎設施。日本擁有先進的核酸技術和高標準的藥品品質。同時，韓國和澳洲則致力於建構轉化醫學、臨床研究和公共衛生基因組學的生態系統。

重點區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協的需求主要受新加坡生物醫學中心以及馬來西亞、泰國、印尼、越南和菲律賓等國診斷技術日益普及的推動。在這些國家，隨著傳染病檢查、學術基因組學研究和臨床研究的進展，對引子、探針和定序試劑的需求不斷成長。在海灣合作理事會（GCC）內部，沙烏地阿拉伯、阿拉伯聯合大公國、卡達及其鄰國正在推進國家級基因組學和精準醫療項目，從而帶動了對定序試劑、合成寡核苷酸、探針和臨床研究工具的需求。

主要寡核苷酸市場主要國家的發展趨勢

美國透過FDA批准、對生物技術領域的資金投入、學術研究以及專業的GMP生產，引領治療性寡核苷酸的商業化進程。同時，加拿大在基因組研究、醫院創新和臨床應用方面也做出了貢獻。墨西哥和巴西是拉丁美洲分子診斷、公共衛生實驗室、感染疾病監測和合約研究的主要需求中心，其中巴西還擁有大規模的學術和生物醫學研究基礎設施。

業界領導者使用的實用建議

產業領導者需要調整產能，以適應從用於藥物發現的寡核苷酸向符合GMP規範的治療產品生產的轉型。優先投資應包括：檢驗的固相合成平台、高解析度純化、質譜分析、雜質表徵、電子批次記錄、資料完整性管理，以及對亞磷醯胺、可控孔徑玻璃、酵素、溶劑和特種試劑等供應商進行嚴格的合格。

調查方法

本執行摘要基於二手研究，研究資料包括監管資料庫、同行評審文獻、臨床實驗室註冊資訊、政府研究計畫、藥典以及業界認可的藥品品質系統標準。研究結果已透過與已知的FDA和EMA寡核苷酸療法先例、已記錄的基因組學相關計劃以及已建立的核酸分析技術進行比對檢驗。

結論

寡核苷酸合成正從專門的研究服務轉向用於精準治療、分子診斷和基因組創新的策略性生產平台。已通過核准的RNA標靶藥物的科學檢驗增強了人們對反義寡核苷酸、siRNA和其他核酸療法的信心，而分子檢測和定序流程也不斷拓展其實際應用場景。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 寡核苷酸合成市場：依產品類型分類

  • 設備/器材
    • DNA/RNA合成器
    • 微陣列合成系統
  • 試劑和耗材
    • 酵素
    • 標記試劑
    • 純化試劑
    • 合成試劑
  • 軟體和服務
    • 生物資訊學工具
    • 雲端儲存和管理解決方案
    • 客製化寡核苷酸合成服務
    • 數據分析平台
  • 合成寡核苷酸
    • DNA寡核苷酸
    • RNA寡核苷酸

第8章：二核苷酸合成市場：依合成規模分類

  • 訂單寡核苷酸合成
  • 大規模/商業化生產

第9章：寡核苷酸合成市場：依遞送方式分類

  • 酵素合成
  • 固相合成

第10章：寡核苷酸合成市場：依應用領域分類

  • 診斷
    • 生物修復
    • 分子影像
    • PCR和定序
  • 藥物發現與開發
    • 先導藥物最適化
    • 目標檢驗
  • 研究
    • 功能基因體學
    • 基因表現分析
    • 基因合成
  • 治療
    • 反義療法
    • 基於 CRISPR 的療法
    • RNA干擾

第11章：寡核苷酸合成市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 診斷實驗室
  • 製藥和生物技術公司

第12章 寡核苷酸合成市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：寡核苷酸合成市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 寡核苷酸合成市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Bio-synthesis Inc.
  • Biocomma Ltd.
  • Biolegio BV
  • Biolytic Lab Performance Inc.
  • Bon Opus Biosciences, LLC
  • Creative Biogene
  • Cusabio Technology LLC
  • Danaher Corporation
  • Eurofins Genomics LLC
  • Eurogentec SA（Kaneka Corporation）
  • GE HealthCare Technologies Inc.
  • Generi BIoTech
  • Genscript Corporation
  • Hongene BIoTech Corp.
  • LGC Genomics Limited
  • Maravai Intermediate Holdings, LLC
  • Merck KGaA
  • Microsynth AG
  • Nitto Denko Avecia Inc.
  • Novartis AG
  • PerkinElmer, Inc.
  • REPROCELL Inc.
  • Synbio Technologies
  • TAG Copenhagen A/S
  • TCI Chemicals Pvt. Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0A609A26A918

The Oligonucleotide Synthesis Market is projected to grow by USD 31.69 billion at a CAGR of 17.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.28 billion
Estimated Year [2026] USD 12.02 billion
Forecast Year [2032] USD 31.69 billion
CAGR (%) 17.43%

Oligonucleotide synthesis is a core enabling technology for precision medicine, molecular diagnostics, synthetic biology, and genomic research. The field covers custom DNA and RNA oligos, antisense oligonucleotides, siRNA, aptamers, CRISPR guide RNAs, primers, probes, and modified nucleic acids produced primarily through solid-phase phosphoramidite chemistry.

Demand is supported by FDA-cleared molecular tests, expanding genomic sequencing workflows, and approved RNA-targeted therapies such as nusinersen, patisiran, givosiran, inclisiran, and tofersen. As therapeutic pipelines mature, buyers increasingly evaluate oligonucleotide synthesis providers on GMP capacity, analytical quality, modification breadth, delivery expertise, regulatory documentation, and supply-chain reliability.

Transformative Shifts in the Oligonucleotide Landscape

The oligonucleotide synthesis landscape is shifting from research-scale custom orders toward clinical and commercial manufacturing. Therapeutic oligos require stringent control of sequence fidelity, impurity profiles, endotoxin, residual solvents, and identity testing by methods such as LC-MS, HPLC, capillary electrophoresis, and NMR.

Manufacturers are investing in higher-throughput synthesizers, greener solvent strategies, automation, closed processing, and integrated CDMO services. At the same time, demand for complex chemistries, including 2'-O-methyl, 2'-MOE, phosphorothioate backbones, LNA, GalNAc conjugates, and chemically modified siRNA, is raising technical requirements and quality expectations across the value chain.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is improving oligonucleotide discovery and manufacturing by accelerating sequence selection, off-target screening, secondary-structure prediction, immunogenicity assessment, and manufacturability evaluation. AI-enabled models are increasingly used with public genomic databases, RNA expression datasets, and high-throughput screening outputs to prioritize candidates before costly wet-lab validation.

In production, machine learning can support real-time process monitoring, predictive maintenance, chromatographic method development, and deviation detection. The strongest near-term value is not replacing validated chemistry, but reducing cycle times, improving batch consistency, strengthening quality-by-design workflows, and helping quality teams interpret complex analytical datasets.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is gaining importance as China, India, Japan, South Korea, and Australia expand genomics, vaccine, and biopharmaceutical capacity. China offers scale, domestic biotech demand, and active nucleic acid research; India contributes cost-competitive manufacturing, clinical research services, and expanding diagnostics infrastructure; Japan maintains advanced nucleic acid science and high-quality pharmaceutical standards; while South Korea and Australia support translational medicine, clinical studies, and public-health genomics ecosystems.

North America remains a leading innovation center because of U.S. FDA experience with RNA-targeted drugs, NIH-funded genomics research, venture-backed biotechnology clusters, and established GMP CDMO infrastructure, with Canada contributing genomics, academic medicine, and clinical translation. Europe is strong in regulatory science, academic translation, and quality manufacturing, supported by EMA oversight and coordinated research programs. Latin America is developing demand through molecular diagnostics, infectious-disease surveillance, and clinical research activity, led by Brazil and Mexico. The Middle East is advancing national genomics, precision medicine, and hospital-based sequencing programs, particularly in Gulf states. Africa is building capacity through public-health sequencing, pathogen surveillance, newborn screening initiatives, and regional laboratory networks, creating a foundation for future oligonucleotide demand.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN demand is led by Singapore's biomedical hub and growing diagnostics adoption across Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where infectious-disease testing, academic genomics, and clinical research are increasing the need for primers, probes, and sequencing reagents. The GCC is advancing national genomics and precision medicine programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring states, supporting demand for sequencing reagents, synthetic oligos, probes, and clinical research tools.

The European Union benefits from harmonized pharmaceutical regulation, Horizon Europe research funding, cross-border health-data initiatives, and strong GMP expectations. BRICS economies provide population scale, manufacturing depth, expanding healthcare access, and growing biotechnology capabilities, with China and India particularly relevant to oligonucleotide production and research supply chains. G7 countries concentrate advanced therapeutic development, regulatory maturity, public biomedical funding, and early adoption of RNA-targeted medicines. NATO members increasingly view biosecurity, resilient supply chains, pathogen surveillance, and dual-use biotechnology governance as strategic priorities, reinforcing the importance of secure oligonucleotide sourcing and quality-controlled nucleic acid manufacturing.

Key Country Insights Across Major Oligonucleotide Markets

The United States leads therapeutic oligonucleotide commercialization through FDA approvals, biotech financing, academic research, and specialized GMP manufacturing, while Canada contributes genomics research, hospital-based innovation, and clinical translation. Mexico and Brazil represent important Latin American demand centers for molecular diagnostics, public-health laboratories, infectious-disease surveillance, and contract research, with Brazil also supported by a large academic and biomedical research base.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong academic science, hospital research networks, clinical trial infrastructure, and regulated biomanufacturing, with Germany and France maintaining deep pharmaceutical and analytical capabilities and the United Kingdom supporting genomics-driven clinical adoption. Russia maintains domestic life-science and pharmaceutical capabilities under constrained international supply conditions, increasing emphasis on localized sourcing and research continuity. In Asia-Pacific, China, India, Japan, Australia, and South Korea are critical markets: China and India are scaling production, research services, and diagnostics capacity; Japan emphasizes innovation, quality, and advanced nucleic acid science; South Korea is expanding biopharmaceutical manufacturing and translational medicine; and Australia supports clinical research, population genomics, and public-health sequencing programs.

Actionable Recommendations for Industry Leaders

Industry leaders should align capacity with the shift from discovery oligos to GMP therapeutic production. Priority investments include validated solid-phase synthesis platforms, high-resolution purification, mass spectrometry, impurity characterization, electronic batch records, data integrity controls, and robust supplier qualification for amidites, controlled-pore glass, enzymes, solvents, and specialty reagents.

Commercial teams should segment customers by research, diagnostic, and therapeutic use cases. Winning providers will combine rapid custom synthesis, regulatory documentation, scalable tech transfer, secure data handling, and expertise in modified RNA, antisense chemistry, siRNA, CRISPR guide RNA, aptamers, probes, and conjugation technologies. Leaders should also strengthen regional redundancy, establish quality agreements early, and integrate AI-enabled design tools with validated laboratory workflows.

Research Methodology

This executive summary is based on secondary research from regulatory databases, peer-reviewed literature, clinical trial registries, government research programs, pharmacopeial references, and recognized industry standards for pharmaceutical quality systems. Insights were cross-checked against known FDA and EMA precedents for oligonucleotide therapeutics, documented genomics initiatives, and established nucleic acid analytical practices.

The analysis evaluates technology drivers, manufacturing shifts, regional adoption patterns, regulatory considerations, and competitive priorities. It emphasizes verifiable evidence, including approved therapeutic modalities, public biomedical programs, validated chemistry platforms, and documented quality requirements, while avoiding unsupported projections, vendor claims, market estimation, market sizing, market share, or forecasting.

Conclusion

Oligonucleotide synthesis is moving from a specialized research service into a strategic manufacturing platform for precision therapeutics, molecular diagnostics, and genomic innovation. Scientific validation from approved RNA-targeted medicines has strengthened confidence in antisense, siRNA, and other nucleic acid modalities, while molecular testing and sequencing workflows continue to expand practical use cases.

Future competitiveness will depend on quality systems, manufacturing scale, chemistry expertise, data-driven development, regulatory readiness, and regional supply resilience. Organizations that integrate AI-enabled design, GMP readiness, analytical rigor, secure data practices, and customer-specific technical support will be best positioned to meet the evolving requirements of oligonucleotide synthesis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oligonucleotide Synthesis Market, by Product Type

  • 7.1. Equipment/Instruments
    • 7.1.1. DNA/RNA Synthesizers
    • 7.1.2. Microarray Synthesizers
  • 7.2. Reagents & Consumables
    • 7.2.1. Enzymes
    • 7.2.2. Labeling Reagents
    • 7.2.3. Purification Reagents
    • 7.2.4. Synthesis Reagents
  • 7.3. Software & Services
    • 7.3.1. Bioinformatics Tools
    • 7.3.2. Cloud Storage & Management Solution
    • 7.3.3. Custom Oligo Synthesis Services
    • 7.3.4. Data Analysis Platforms
  • 7.4. Synthesized Oligonucleotides
    • 7.4.1. DNA Oligonucleotides
    • 7.4.2. RNA Oligonucleotides

8. Oligonucleotide Synthesis Market, by Synthesis Scale

  • 8.1. Custom Oligonucleotide Synthesis
  • 8.2. Large-Scale/Commercial Manufacturing

9. Oligonucleotide Synthesis Market, by Delivery Method

  • 9.1. Enzymatic Synthesis
  • 9.2. Solid-Phase Synthesis

10. Oligonucleotide Synthesis Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Biosensors
    • 10.1.2. Molecular Imaging
    • 10.1.3. PCR & Sequencing
  • 10.2. Drug Discovery & Development
    • 10.2.1. Lead Optimization
    • 10.2.2. Target Validation
  • 10.3. Research
    • 10.3.1. Functional Genomics
    • 10.3.2. Gene Expression Analysis
    • 10.3.3. Gene Synthesis
  • 10.4. Therapeutics
    • 10.4.1. Antisense Therapy
    • 10.4.2. CRISPR-Based Therapeutics
    • 10.4.3. RNA Interference

11. Oligonucleotide Synthesis Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Oligonucleotide Synthesis Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Oligonucleotide Synthesis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oligonucleotide Synthesis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Agilent Technologies, Inc.
  • 16.2. Ajinomoto Bio-Pharma Services
  • 16.3. Bio-synthesis Inc.
  • 16.4. Biocomma Ltd.
  • 16.5. Biolegio B.V.
  • 16.6. Biolytic Lab Performance Inc.
  • 16.7. Bon Opus Biosciences, LLC
  • 16.8. Creative Biogene
  • 16.9. Cusabio Technology LLC
  • 16.10. Danaher Corporation
  • 16.11. Eurofins Genomics LLC
  • 16.12. Eurogentec S.A. by Kaneka Corporation
  • 16.13. GE HealthCare Technologies Inc.
  • 16.14. Generi Biotech
  • 16.15. Genscript Corporation
  • 16.16. Hongene Biotech Corp.
  • 16.17. LGC Genomics Limited
  • 16.18. Maravai Intermediate Holdings, LLC
  • 16.19. Merck KGaA
  • 16.20. Microsynth AG
  • 16.21. Nitto Denko Avecia Inc.
  • 16.22. Novartis AG
  • 16.23. PerkinElmer, Inc.
  • 16.24. REPROCELL Inc.
  • 16.25. Synbio Technologies
  • 16.26. TAG Copenhagen A/S
  • 16.27. TCI Chemicals Pvt. Ltd.
  • 16.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUIPMENT/INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA/RNA SYNTHESIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROARRAY SYNTHESIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LABELING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LABELING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LABELING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PURIFICATION REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHESIS REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOINFORMATICS TOOLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLOUD STORAGE & MANAGEMENT SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CUSTOM OLIGO SYNTHESIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DATA ANALYSIS PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CUSTOM OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LARGE-SCALE/COMMERCIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYMATIC SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLID-PHASE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOSENSORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOSENSORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOSENSORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PCR & SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PCR & SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PCR & SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FUNCTIONAL GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTISENSE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RNA INTERFERENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA INTERFERENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RNA INTERFERENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 228. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 236. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 270. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 274. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 277. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 278. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 280. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 291. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 292. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY EQUIPMENT/INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIZED OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY SYNTHESIS SCALE, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCT TYPE, 2018-2